The transaction amounts to 365 million euros and 35 million if certain milestones met
The pharmaceutical Almirall has closed the deal to acquire the entire share capital of Poli Group Holding, the holding company Poly Group, as reported Monday the pharmaceutical to the National Securities Market Commission (CNMV).
At the end of last November, the company estimated the amount of the acquisition of 365 million euros, with the possibility of payment of 35 million euros in the case met certain milestones related to the development of the business.
This transaction achieves a structure Almirall R & D focused on dermatology, a proprietary technology and three drug products under development.
Poli Group, based in Lugano (Switzerland) and sells products in 70 countries, comprising three companies: Taurus Pharma GbmH, Polichem SA and Polichem. With it you get a structure Almirall R & D focused on dermatology, a proprietary technology and a pipeline of three clinical trials in the final stages of development.
The Swiss company generated between June 2014 and June 2015 net sales of about 85 million euros. The group has mainly specialized in dermatology products, and a powerful portfolio of gynecological and respiratory products.
Europe and Asia are the focus of the company, which has a diversified portfolio of proprietary drugs focused on dermatology. These are complemented by a “strong” portfolio of gynecological and respiratory products, as highlighted Almirall.
Courtesy Car Service Barcelona